See more : Meiho Facility Works Ltd. (1717.T) Income Statement Analysis – Financial Results
Complete financial analysis of EKF Diagnostics Holdings plc (EKF.L) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of EKF Diagnostics Holdings plc, a leading company in the Medical – Devices industry within the Healthcare sector.
- Xinjiang Tianshan Animal Husbandry Bio-engineering Co., Ltd. (300313.SZ) Income Statement Analysis – Financial Results
- Denarius Metals Corp. (DNRSF) Income Statement Analysis – Financial Results
- Imagexpres Corp. (IMJX) Income Statement Analysis – Financial Results
- Aster DM Healthcare Limited (ASTERDM.NS) Income Statement Analysis – Financial Results
- EnQuest PLC (ENQ.L) Income Statement Analysis – Financial Results
EKF Diagnostics Holdings plc (EKF.L)
About EKF Diagnostics Holdings plc
EKF Diagnostics Holdings plc designs, develops, manufactures, and sells diagnostic instruments, reagents, and other ancillary products in Europe, the Middle East, the Americas, Asia, Africa, and internationally. It offers DiaSpect Tm hand-held hemoglobin analyzer; DiaSpect Hemoglobin T analyzer; Hemo Control, a hemoglobin analyzer that provides quantitative and lab quality hemoglobin results; and HemataStat II, a microhematocrit centrifuge that provides a quantitative hematocrit reading for six blood samples. The company also provides glucose and lactate analyzers, such as Biosen C-Line GP+ and C-Line Clinic; Quo-Lab A1c, a desktop point-of-care analyzer for measuring glycated hemoglobin; Quo-Test A1c for the monitoring and management of diabetes; and STAT-Site M Beta-hydroxybutyrate analyzer. In addition, it offers Creamatocrit Plus, an analyzer for detecting the lipid concentration and calorific density in mothers' milk; QuPID and True20 pregnancy tests; and Lactate Scout 4, a lactate analyzer. Further, the company provides clinical chemical analyzers, such as Beta-hydroxybutyrate for monitoring ketosis; Glycated Albumin; Glycated Serum Protein; Nitro-tab Ketone tablets; and Procalcitonin marker for bacterial infection and sepsis, as well as reagents, calibrators, standards, and controls. Additionally, it offers RaPET Serology immunoassay kits; QuStick Strep A for Strep A infection treatment; Altair 240, a chemistry analyzer; Excel, a semi-automated chemistry analyzer; Micro 12, a micro centrifuge for clinical, molecular, and bacteriological applications; Hema-Screen Serology, an analyzer dependent for early detection of colorectal cancer; Uri-Trak 120 urine analyzer; and kits and other services related to COVID-19, as well as contract manufacturing solutions to third-party businesses and laboratory services. The company was founded in 1990 and is headquartered in Cardiff, the United Kingdom.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 52.61M | 66.64M | 81.84M | 65.26M | 44.92M | 42.54M | 41.58M | 38.59M | 30.05M | 40.06M | 31.80M | 26.06M | 21.66M | 6.48M | 0.00 | 465.00K | 341.00K | 3.08M | 3.26M | 2.24M | 1.28M | 1.62M | 1.10M |
| Cost of Revenue | 28.75M | 42.60M | 42.47M | 27.84M | 21.19M | 19.85M | 18.72M | 20.27M | 15.38M | 20.11M | 15.46M | 11.75M | 11.28M | 3.57M | 0.00 | 0.00 | 0.00 | 1.50M | 1.29M | 561.00K | 176.00K | 0.00 | 0.00 |
| Gross Profit | 23.86M | 24.04M | 39.37M | 37.42M | 23.73M | 22.70M | 22.86M | 18.32M | 14.67M | 19.95M | 16.35M | 14.31M | 10.38M | 2.91M | 0.00 | 465.00K | 341.00K | 1.57M | 1.98M | 1.67M | 1.10M | 1.62M | 1.10M |
| Gross Profit Ratio | 45.35% | 36.07% | 48.10% | 57.34% | 52.82% | 53.35% | 54.98% | 47.48% | 48.82% | 49.80% | 51.39% | 54.92% | 47.93% | 44.90% | 0.00% | 100.00% | 100.00% | 51.15% | 60.56% | 74.90% | 86.20% | 100.00% | 100.00% |
| Research & Development | 1.82M | 1.52M | 1.38M | 1.44M | 2.27M | 1.64M | 2.20M | 2.04M | 2.35M | 0.00 | 0.00 | 0.00 | 269.00K | 143.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 19.68M | 23.18M | 17.71M | 20.66M | 18.28M | 10.59M | 18.19M | 18.73M | 29.16M | 22.79M | 14.44M | 14.65M | 9.30M | 2.39M | 386.00K | 30.00K | 0.00 | 894.00K | 1.40M | 1.96M | 1.32M | 1.19M | 626.00K |
| Selling & Marketing | -1.80M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 17.88M | 23.18M | 17.71M | 20.66M | 18.28M | 10.59M | 18.19M | 18.73M | 29.16M | 22.79M | 14.44M | 14.65M | 9.30M | 2.39M | 386.00K | 30.00K | 0.00 | 894.00K | 1.40M | 1.96M | 1.32M | 1.19M | 626.00K |
| Other Expenses | 2.08M | -919.00K | -90.00K | -133.00K | -337.00K | -89.00K | -52.00K | -85.00K | -139.00K | -371.00K | -495.00K | -542.00K | 2.46M | 730.00K | 432.00K | 978.00K | 1.66M | 215.00K | 62.00K | 0.00 | 0.00 | -457.00K | 0.00 |
| Operating Expenses | 21.78M | 22.26M | 17.62M | 20.53M | 17.94M | 10.50M | 18.13M | 18.65M | 29.02M | 22.42M | 13.94M | 14.11M | 12.82M | 6.42M | 736.00K | 1.94M | 163.00K | 867.00K | 514.00K | 1.96M | 1.46M | 1.19M | 626.00K |
| Cost & Expenses | 50.53M | 64.86M | 60.09M | 48.37M | 39.13M | 30.34M | 36.86M | 38.92M | 44.39M | 42.54M | 29.40M | 25.86M | 12.82M | 6.42M | 736.00K | 1.94M | 163.00K | 867.00K | 514.00K | 1.96M | 1.46M | 1.19M | 626.00K |
| Interest Income | 125.00K | 131.00K | 45.00K | 53.00K | 73.00K | 43.00K | 53.00K | 37.00K | 35.00K | 18.00K | 5.00K | 4.00K | 76.00K | 28.00K | 29.00K | 86.00K | 50.00K | 0.00 | 6.00K | 0.00 | 0.00 | 1.00K | 0.00 |
| Interest Expense | 75.00K | 102.00K | 357.00K | 1.59M | 339.00K | 35.00K | 106.00K | 505.00K | 370.00K | 298.00K | 364.00K | 144.00K | 396.00K | 187.00K | 1.00K | 1.08M | 7.00K | 4.00K | 77.00K | 216.00K | 166.00K | 95.00K | 167.00K |
| Depreciation & Amortization | 5.47M | 6.66M | 5.89M | 4.61M | 4.44M | 3.99M | 4.02M | 4.96M | 8.05M | 4.95M | 3.55M | 3.08M | 2.32M | 1.17M | 3.00K | 3.00K | 3.00K | 5.00K | 6.00K | 7.00K | 9.00K | 7.00K | 7.00K |
| EBITDA | 7.68M | -2.18M | 27.39M | 20.04M | 10.02M | 16.19M | 8.43M | 4.46M | -7.35M | 1.75M | 4.52M | 3.03M | 187.00K | -1.11M | -273.00K | -920.00K | -110.00K | 591.00K | 998.00K | -282.00K | -283.00K | 437.00K | 479.00K |
| EBITDA Ratio | 14.59% | 12.86% | 33.82% | 33.04% | 22.93% | 38.16% | 22.62% | 12.10% | -25.77% | 1.86% | 16.59% | 11.62% | -50.30% | -105.45% | 0.00% | -516.77% | 53.08% | -24.08% | -1.20% | -87.83% | -119.92% | -73.02% | -56.48% |
| Operating Income | 2.08M | 1.91M | 21.75M | 16.90M | 5.78M | 12.20M | 4.73M | -327.00K | -14.35M | -2.47M | 2.40M | 204.00K | -2.04M | -1.93M | -596.00K | -1.01M | -163.00K | 586.00K | 986.00K | -289.00K | -292.00K | 429.00K | 470.00K |
| Operating Income Ratio | 3.96% | 2.87% | 26.57% | 25.89% | 12.88% | 28.67% | 11.37% | -0.85% | -47.76% | -6.17% | 7.55% | 0.78% | -9.42% | -29.77% | 0.00% | -216.99% | -47.80% | 19.04% | 30.24% | -12.93% | -22.90% | 26.55% | 42.88% |
| Total Other Income/Expenses | 50.00K | -10.85M | -312.00K | -1.54M | -266.00K | -34.00K | -422.00K | -676.00K | -1.42M | -1.49M | -1.79M | -400.00K | -320.00K | -1.65M | 183.00K | 86.00K | 43.00K | 117.00K | -71.00K | -216.00K | -166.00K | -94.00K | -167.00K |
| Income Before Tax | 2.13M | -8.94M | 21.44M | 15.36M | 5.52M | 12.17M | 4.31M | -1.00M | -15.77M | -4.03M | 607.00K | -196.00K | -2.36M | -2.09M | -568.00K | -923.00K | -120.00K | 582.00K | 915.00K | -505.00K | -458.00K | 335.00K | 303.00K |
| Income Before Tax Ratio | 4.05% | -13.42% | 26.19% | 23.53% | 12.28% | 28.59% | 10.36% | -2.60% | -52.49% | -10.05% | 1.91% | -0.75% | -10.90% | -32.22% | 0.00% | -198.49% | -35.19% | 18.91% | 28.06% | -22.60% | -35.92% | 20.73% | 27.65% |
| Income Tax Expense | -600.00K | 634.00K | 5.28M | 3.97M | 1.59M | 1.87M | 1.37M | -1.17M | -2.21M | 1.44M | 1.50M | -606.00K | 198.00K | -49.00K | -75.00K | 146.00K | 150.00K | -14.00K | 142.00K | 84.00K | 17.00K | 192.00K | 9.00K |
| Net Income | 2.35M | -9.58M | 15.85M | 11.11M | 3.68M | 10.11M | 2.72M | -18.00K | -37.12M | -5.69M | -1.13M | 1.83M | -2.88M | -3.44M | -203.00K | -1.31M | 465.00K | 596.00K | 773.00K | -589.00K | -475.00K | 143.00K | 294.00K |
| Net Income Ratio | 4.47% | -14.37% | 19.37% | 17.03% | 8.19% | 23.76% | 6.53% | -0.05% | -123.56% | -14.20% | -3.54% | 7.02% | -13.32% | -52.98% | 0.00% | -281.08% | 136.36% | 19.37% | 23.70% | -26.35% | -37.25% | 8.85% | 26.82% |
| EPS | 0.01 | -0.02 | 0.03 | 0.02 | 0.01 | 0.02 | 0.01 | 0.00 | -0.09 | -0.02 | 0.00 | 0.01 | -0.01 | -0.04 | -0.01 | -0.04 | 0.01 | 0.02 | 0.02 | -0.02 | -0.02 | 0.02 | 0.00 |
| EPS Diluted | 0.01 | -0.02 | 0.03 | 0.02 | 0.01 | 0.02 | 0.01 | 0.00 | -0.09 | -0.01 | 0.00 | 0.01 | -0.01 | -0.04 | -0.01 | -0.04 | 0.01 | 0.02 | 0.02 | -0.02 | -0.02 | 0.02 | 0.00 |
| Weighted Avg Shares Out | 454.11M | 457.18M | 457.00M | 454.52M | 454.09M | 457.21M | 463.10M | 446.04M | 422.06M | 379.63M | 286.30M | 269.01M | 213.58M | 97.80M | 34.29M | 33.59M | 33.59M | 33.59M | 33.34M | 33.34M | 27.56M | 5.96M | 147.00M |
| Weighted Avg Shares Out (Dil) | 454.11M | 457.18M | 460.96M | 458.80M | 458.41M | 461.49M | 469.34M | 450.09M | 422.06M | 393.51M | 286.30M | 269.01M | 213.58M | 97.80M | 34.29M | 33.59M | 33.59M | 33.60M | 33.35M | 33.34M | 27.56M | 5.96M | 147.00M |
Source: https://incomestatements.info
Category: Stock Reports